Mariia N. Lunkova , Elena V. Litviakova , S.A. Ivanov , A.D. Kaprin , Maksim S. Denisov , Marina V. Kiseleva
Abstract
Breast cancer (BC) treatment implies an integrated approach that involves inclusion of surgical techniques, radiation therapy, chemotherapy, endocrine therapy, targeted therapy, and in some cases immunotherapy in the treatment plan, while selection of treatment tactics depends on the tumor biological subtype, neoplastic process extension, and somatic status of the patient. The paper provides analysis of Russian clinical guidelines and advanced treatment regimens for primary operable BC that are based on the principle of case-by-case selection in each clinical situation considering the disease stage, tumor molecular subtype and the goals set by an expert specialist.
Key words: primary operable breast cancer, chemotherapy, case-by-case approach.
Key words: primary operable breast cancer, chemotherapy, case-by-case approach.
About the Author
Mariia N. Lunkova 1 , Elena V. Litviakova 1 , S.A. Ivanov 2 , A.D. Kaprin 3 , Maksim S. Denisov 1 , Marina V. Kiseleva 11 Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Obninsk, Russia
2 Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Obninsk, Russia; National Medical Research Center of Radiology, Obninsk, Russia
3 Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russia; National Medical Research Center of Radiology, Obninsk, Russia; Herzen Moscow Research Oncology Institute, Moscow, Russia
References
1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.
[Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Zlokachestvennye novoobrazovaniia v Rossii v 2021 godu (zabolevaemost' i smertnost'). M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2022 (in Russian).]
2. Lynch HT, Snyder C, Lynch J. Hereditary breast cancer: practical pursuit for clinical translation. Ann Surg Oncol 2012; 19 (6): 1723–31.
3. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition (UIJCC).
4. Gradishar WJ et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18 (4): 452–78.
5. Sparano JA et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358 (16): 1663–71.
6. Citron ML, Berry DA, Cirrincione С et al. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. J Clin Oncol 2005; 23 (Suppl. 16): 620.
7. Curigliano G et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28 (8): 1700–12.
8. Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. Практические рекомендации RUSSCO. 2019; 9 (3s2): 128–63.
[Stenina M.B., Zhukova L.G., Koroleva I.A. i dr. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu invazivnogo raka molochnoi zhelezy. Zlokachestvennye opukholi. Prakticheskie rekomendatsii RUSSCO. 2019; 9 (3s2): 128–63 (in Russian).]
9. Ferreira Filho AF et al. The feasibility of classical cyclophosphamide, methotrexate, 5- fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. Ann Oncol 2002; 13 (3): 416–21.
10. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29 (25): 3366.
11. Vriens BEPJ et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat 2017; 165 (3): 593–600.
12. Von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German breast group. J Clin Oncol 2005; 23: 2676–85.
13. Sikov WM, Berry DA, Perou CM et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once per Week Paclitaxel Followed by Dose Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol 2014; 33 (1): 13–21.
14. Spring L, Niemierko A, Comander AH et al. Tolerability and effectiveness of pertuzumab containing neoadjuvant (NA) regimens vs. AC TH for HER2 positive (+) localized breast cancer (BC) [ASCO abstr. 586]. J Clin Oncol 2016; 34.
15. Sugitani I et al. Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety. Int J Clin Oncol 2017; 22 (5): 880–6.
16. Schneeweiss A et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24 (9): 2278–84.
17. Hussain N et al. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Int J Breast Cancer 2018; 2018: 6106041.
18. Lluch A et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 2020; 38 (3): 203–13.
19. Jones SE et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. J Clin Oncol 2006; 24 (34): 5381–7.
20. Van Rossum AGJ et al. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). Eur J Cancer 2018; 102: 40–8.
21. Watanabe T et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer 2017; 123 (5): 759–68.
22. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14): 1273–83. DOI: 10.1056/NEJMoa0910383
23. Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673–84.
24. Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372 (2): 134–41.
25. Jones SE et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 2013; 14 (11): 1121–8.
26. Myers RE et al. Baseline staging tests in primary breast cancer: a practice guideline. Can Med Assoc J 2001; 164 (10): 1439–44.
27. Dang C et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008; 26 (8): 1216–22.
28. Von Minckwitz G, Procter M, de Azambuja E. Adjuvant Pertuzumab and Trastuzumab in Early HER2 Positive Breast Cancer. N Engl J Med 2017; 377 (2): 122–31.
29. Von Minckwitz G et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380 (7): 617–28.
30. Boccardo F et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol 1999; 43 (6): 461–6.
31. DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol 2019; 37 (19): 1629–37.
32. Cluze C, Rey D, Huiart L et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012; 23: 882–90.
33. Davies C et al. Adjuvant tamoxifen: longer against shorter (ATLAS) collaborative group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381 (9869): 805–16.
34. Regan MM, Francis PA, Pagani O et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016; 34: 2221–31.
35. Gray R et al. aTTom Collaborative Group (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (Suppl. 18): 5.
36. Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010; 36 (3): 249–61.
37. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006; 94 (4): 460–4.
38. Mamounas E et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006; 7 (5): 416–21.
For citation:Lunkova M.N., Litviakova E.V., Ivanov S.A., Kaprin A.D., Denisov M.S., Kiseleva M.V. Practical guidelines on drug treatment of primary operable breast cancer. Clinical review for general practice. 2023; 4 (12): 10–18 (In Russ.). DOI: 10.47407/kr2023.4.12.00324
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.